These technological advances collectively support the feasibility of developing miRNA-based therapies and may augment the therapeutic potential of miR-1 to suppress UHRF1-mediated epigenetic dysregulation in CCA. This evidence concerns the gene UHRF1 and cholangiocarcinoma.